Extracorporeal membrane oxygenation (ECMO) has been successful as a rescue therapy for infants with respiratory failure with some diagnoses such as meconium aspiration syndrome (MAS) having a survival rate of more than 94%. New therapies have allowed many infants who would have required ECMO to be kept off ECMO, but at what cost. The survival rate for the neonatal ECMO patient has dropped over the years, whereas the time of ECMO has increased, indicating that the new therapies are keeping the less ill infants off ECMO. The major cause of non-survival in this population remains intraventricular hemorrhage. The primary risk factors related to this are thought to be pre-ECMO events, such as hypoxia and/or ischemia either prenatally or post-delivery. ECMO events that may complicate this are heparinization that is required while on ECMO and concern for the effect of shear stress and blood flow pattern changes created by the ECMO pump with venoarterial ECMO, although these changes are not seen in venovenous ECMO, the more common form of ECMO. Newer low-resistant microporous artificial lungs and miniaturized pumping systems may allow ECMO to be performed using less blood and safer equipment. The smaller low-resistant artificial lungs provide the ability to consider giving extracorporeal life support using only this membrane with flow provided by an arterial-venous shunt, thus eliminating the pumping system all together. Trials are ongoing in adults and, if effective, may direct further research into using this technique in newborns where the umbilical artery and vein could be used as the arterial-venous shunt.
Introduction
Extracorporeal membrane oxygenation (ECMO) is the use of a modified cardiopulmonary bypass circuit to supply respiratory and/or cardiac support for patients in cardiorespiratory failure. 1 The ECMO circuit supplies an artificial lung and an artificial pump, which allow the patient to be supported for both respiratory and cardiac needs. On account of this, many describe ECMO therapy as a 'time-buying' procedure. If you give extracorporeally respiratory and cardiac support to the level, the patient can be placed on minimal ventilatory and pressor therapy over time, and a percentage of the patients will have recovery of lung and/or cardiac function. As all patients have to be systemically heparinized to be on an ECMO circuit, the known vasodilatory effect of heparin on the pulmonary vessels may assist in the reduction of pulmonary vascular resistance in patients placed on ECMO. 2 In the mid-1960s, ECMO use was directed at the premature infant with the hopes that ECMO would provide the 'artificial' placenta for these infants. 3, 4 Although the procedure provided sufficient cardiorespiratory support for these infants, all infants died secondary to the high intracranial hemorrhage (ICH) rate in the premature population. This was thought to be related to the immature brain of these infants with an already high rate of ICH and to the heparinization required for the procedure. The first newborn survivor in 1976 was an infant with meconium aspiration syndrome (MAS), turning the focus of treatment to the term infant. 5 Why would MAS be a good disease to treat with a therapy such as ECMO? Figure 1 depicts the complex pathophysiology associated with MAS, with a combination of obstructive lung disease, parenchymal disease caused by inflammation and persistent pulmonary hypertension. Ventilation alone, either conventional or high-frequency ventilation, of the severe cases may not be able to break the cycle associated with severe hypoxia and persistent pulmonary hypertension, thus making ECMO an ideal therapy for this complex disease. While on ECMO, the ventilator can be placed at lung rest, allowing gentle ventilation, time for the body to absorb the meconium and time for the pulmonary hypertension to resolve. Figure 2 from the Extracorporeal Life Support Organization database shows the changing patterns of use in ECMO, with the MAS infant ranging from 45 to now 35% of the neonatal patients treated with ECMO. The survival rate for MAS infants compared with infants with other disease states is shown in Figure 3 . Infants with MAS, who do not survive ECMO, do not do so because of a major intracranial complication, not because of irreversibility of the lung disease. These findings indicate that infants with severe MAS need to be referred to an ECMO center prior to meeting conventional ECMO criteria to reduce the risk for pre-ECMO cardiovascular instability making transfer difficult. Most intracranial bleeds are thought to be secondary to hypoxic/ ischemic insults prior to ECMO that would, in a non-heparinized patient, result in an infarction, but in the heparinized ECMO population results in a hemorrhage and/or hemorrhagic infarction. 6, 7 Studies are now indicating that ECMO conducted using venoarterial (VA) ECMO, in which non-pulsatile flow is created with the ECMO pump, may also place the brain at risk. [7] [8] [9] [10] [11] This risk is minimal in venovenous (VV) ECMO, the more common form of ECMO for the infant with MAS.
As new therapies have become available, such as the use of high-frequency ventilation, surfactant use in term infants, and inhaled nitric oxide, the need for ECMO has reduced. 1,12 -15 Figure 4 shows the reduction in the number of infants being placed on ECMO over time. Also depicted in this figure is the reduction in the survival rate of the ECMO patient over time. Although the cause of this reduction is not clear, it may be assumed that as increasing numbers are rescued by other therapies, the severity and acuity of the patients going on to ECMO has increased. This finding differs from those of Fliman et al., 15 who only looked at cases from 1996 to 2003. This difference in survival data is probably related to the time period studied, with the late 1980s, as depicted in Figure 4 , representing the highest survival rate prior to most new interventions. Figure 5 may support the theory of sicker patients now being placed on ECMO. This figure shows that as the number of ECMO patients has decreased, the time on ECMO has increased, indicating that the severity of lung disease in infants going on ECMO is greater, that is, the less severe are being rescued by other therapies. Table 1 compares the pre-ECMO ventilator and blood gas data for the top three diagnoses going on to ECMO. It is interesting that the MAS infant has an average mean airway pressure of 16 compared with the congenital diaphragmatic infant with a mean airway pressure of 15 mm Hg, indicating the severity of the lung disease in these infants. The risk for cerebral injury in the ECMO population ranges from 5 to 12%, with severe hypoxia, birth weight and sepsis representing the highest risk factors. 6 Although the pre-ECMO events are thought to be the primary factors leading to ICH, data from animal models simulating clinical ECMO have shown an altered cerebral autoregulation pattern in animals exposed to VA ECMO both with and without prior exposure to hypoxia. [7] [8] [9] [10] [11] Figure 6 depicts the changes in cerebral blood flow with lower cerebral perfusion pressure (lower end of the autoregulatory curve).
In the newborn lamb model, 2 h of exposure to severe hypoxia altered cerebral autoregulation, but when the animals were recovered by placing them on ECMO, the alteration in autoregulation was markedly worse. Further studies using isolated Figure 5 As survival (line) has decreased, time on extracorporeal membrane oxygenation (ECMO) has increased over the years (black bar) (data from the Extracorporeal Life Support Organization database January summary report, n ¼ 21 258 patients). iNO, inhaled nitric oxide. arterial vascular chamber techniques have shown that cerebral vessels taken from animals exposed to VA ECMO have a marked alteration in reactivity and that this reactivity is associated with an altered production of nitric oxide (see Figure 7) . [10] [11] [12] This alteration is thought to be secondary to the shear stress changes caused by the non-pulsatile VA ECMO circuit, because this alteration is seen only in the VA ECMO-exposed animals and not to animals exposed to VV ECMO, in which the pumping chamber is the native heart with normal pulsatile blood flow patterns (see Figure 7) . [10] [11] [12] These findings indicate that patients placed on VA ECMO may have an alteration of cerebral vascular reactivity resulting in altered autoregulation of the cerebral circulation. The cerebral circulation becomes pressure-passive under these conditions, making hypertension and hypotension risks for either cerebral ischemia (infarction) or cerebral overperfusion (cerebral hemorrhage). There has been no randomized comparison of VA versus VV ECMO patients to determine whether the incidence of ICH is higher in the VA ECMO population. Many centers still use VA ECMO primarily, but when they use VV ECMO, it is in the less severe infants, making a comparison of the rate of ICH in these populations difficult. A recent study by Radhakrishnan et al., 16 reviewing data from the Extracorporeal Life Support Organization's registry on the outcome and complication rate in the MAS population treated with ECMO, found that infants with MAS were treated with VV ECMO 55% of the time compared with 29% for the non-MAS patient. They also found that the MAS population had a significantly higher survival rate and lower number of complications per patient versus the non-MAS patient. They concluded that, with the lower mortality and morbidity, it was time to consider relaxing the criteria for the MAS patient and ECMO use. This may be a consideration when using VV ECMO, in which potential cerebral alterations do not exist and ligation of the carotid artery is not a concern. It may be time to consider a randomized trial looking at morbidity instead of mortality in this population. Although MAS is the most common neonatal respiratory failure diagnoses going on in ECMO, the increasing use of ECMO is now in neonatal and pediatric patients with heart failure post-surgery for congenital heart disease. 17 With this increase, there has been the introduction of newer devices for cardiovascular support Figure 6 Lamb studies of cerebral autoregulation after prolonged hypoxia and recovery using extracorporeal membrane oxygenation (ECMO) therapy. Control animals (circle) autoregulated down to cerebral perfusion pressures of <25 mm Hg, whereas animals exposed to hypoxia (square) and recovered with increasing fractional inspired oxygen (FIO2) could only autoregulate down to cerebral perfusion pressure (CPP) of 25 to 39. If animals were exposed to hypoxia and then recovered with ECMO, the alteration would be much worse with loss of autoregulation at a CPP of 40 to 55 mm Hg. Isolated vessel chamber studies on lamb middle cerebral arteries taken from animals exposed to no extracorporeal membrane oxygenation (ECMO) (controls), venoarterial (VA) or venovenous (VV) ECMO are shown in this figure. Vessels were exposed to acetylcholine (Ach) and monitored for dilation. Percent change in vessel diameter is noted on the Y axis. 11, 12 including various types of ventricular assist devices. Artificial heart support for bridge to transplant available for the adult population is now available for the newborn and pediatric population in Europe. Research and development of similar devices is ongoing in the United States. The field of conventional ECMO is also changing, with newer equipment, including low-resistant microporous oxygenators and centrifugal pumps that will allow the procedure to be performed with smaller and safer systems. 18 Newer low-resistant microporous membrane lungs have the ability of allowing ECMO to be conducted without a pump. [19] [20] [21] On account of the low resistance of these membranes, gas transfer can be achieved through an arterial-venous shunt through these membranes. These techniques are presently used in clinical trials in the adult population in Europe and have shown good success with survival rates as high as 70% is some studies. [19] [20] [21] If the results of these studies show improvement in outcome, the use of a non-pump-driven circuit with potentially less complications and lower blood prime may allow for the consideration of studies using extracorporeal support for early intervention instead as a rescue therapy. These trials would be designed to look at reduction in the lung injury, time of ventilation and reduction in hospital length of stay. To date, this technique has not been used in newborns, but the umbilical vessels make this an attractive approach. The MAS population would be perfect candidates to consider for such a study.
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